vs

Side-by-side financial comparison of BillionToOne, Inc. (BLLN) and California Resources Corp (CRC). Click either name above to swap in a different company.

California Resources Corp is the larger business by last-quarter revenue ($119.0M vs $83.5M, roughly 1.4× BillionToOne, Inc.). BillionToOne, Inc. produced more free cash flow last quarter ($6.5M vs $-32.0M).

BillionToOne, Inc. is a life sciences and molecular diagnostics firm developing high-precision genetic testing solutions. Its core offerings include non-invasive prenatal tests, oncology diagnostics, and rare disease screening, serving clinical providers and patients mainly in North America.

California Resources Corporation is an American energy corporation engaged in hydrocarbon exploration in California. It is organized in Delaware and headquartered in Long Beach, California. Its mineral acreage holdings in California constitute the largest privately held position in the state.

BLLN vs CRC — Head-to-Head

Bigger by revenue
CRC
CRC
1.4× larger
CRC
$119.0M
$83.5M
BLLN
More free cash flow
BLLN
BLLN
$38.5M more FCF
BLLN
$6.5M
$-32.0M
CRC

Income Statement — Q3 FY2025 vs Q1 FY2026

Metric
BLLN
BLLN
CRC
CRC
Revenue
$83.5M
$119.0M
Net Profit
$5.7M
Gross Margin
69.9%
Operating Margin
11.5%
-597.5%
Net Margin
6.8%
Revenue YoY
117.4%
Net Profit YoY
138.3%
EPS (diluted)
$0.10
$-8.02

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BLLN
BLLN
CRC
CRC
Q1 26
$119.0M
Q4 25
$679.0M
Q3 25
$83.5M
$715.0M
Q2 25
$702.0M
Q1 25
$814.0M
Q4 24
$45.1M
$826.0M
Q3 24
$38.4M
$870.0M
Q2 24
$412.0M
Net Profit
BLLN
BLLN
CRC
CRC
Q1 26
Q4 25
$12.0M
Q3 25
$5.7M
$64.0M
Q2 25
$172.0M
Q1 25
$115.0M
Q4 24
$-11.5M
$33.0M
Q3 24
$-14.9M
$345.0M
Q2 24
$8.0M
Gross Margin
BLLN
BLLN
CRC
CRC
Q1 26
Q4 25
Q3 25
69.9%
Q2 25
Q1 25
Q4 24
57.1%
Q3 24
52.6%
Q2 24
Operating Margin
BLLN
BLLN
CRC
CRC
Q1 26
-597.5%
Q4 25
6.9%
Q3 25
11.5%
13.7%
Q2 25
38.0%
Q1 25
22.9%
Q4 24
17.0%
8.2%
Q3 24
-32.9%
59.5%
Q2 24
9.2%
Net Margin
BLLN
BLLN
CRC
CRC
Q1 26
Q4 25
1.8%
Q3 25
6.8%
9.0%
Q2 25
24.5%
Q1 25
14.1%
Q4 24
-25.5%
4.0%
Q3 24
-38.8%
39.7%
Q2 24
1.9%
EPS (diluted)
BLLN
BLLN
CRC
CRC
Q1 26
$-8.02
Q4 25
$0.21
Q3 25
$0.10
$0.76
Q2 25
$1.92
Q1 25
$1.26
Q4 24
$-1.13
$0.87
Q3 24
$-1.47
$3.78
Q2 24
$0.11

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BLLN
BLLN
CRC
CRC
Cash + ST InvestmentsLiquidity on hand
$195.2M
Total DebtLower is stronger
$55.0M
Stockholders' EquityBook value
$-239.5M
$2.9B
Total Assets
$327.5M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BLLN
BLLN
CRC
CRC
Q1 26
Q4 25
$132.0M
Q3 25
$195.2M
$196.0M
Q2 25
$72.0M
Q1 25
$214.0M
Q4 24
$191.5M
$372.0M
Q3 24
$241.0M
Q2 24
$1.0B
Total Debt
BLLN
BLLN
CRC
CRC
Q1 26
Q4 25
Q3 25
$55.0M
$1.0B
Q2 25
$1.0B
Q1 25
$1.0B
Q4 24
$51.5M
$1.1B
Q3 24
$1.1B
Q2 24
$1.2B
Stockholders' Equity
BLLN
BLLN
CRC
CRC
Q1 26
$2.9B
Q4 25
$3.7B
Q3 25
$-239.5M
$3.4B
Q2 25
$3.4B
Q1 25
$3.5B
Q4 24
$-251.7M
$3.5B
Q3 24
$-242.9M
$3.5B
Q2 24
$2.1B
Total Assets
BLLN
BLLN
CRC
CRC
Q1 26
Q4 25
$7.4B
Q3 25
$327.5M
$6.8B
Q2 25
$6.7B
Q1 25
$6.8B
Q4 24
$302.1M
$7.1B
Q3 24
$7.1B
Q2 24
$4.5B
Debt / Equity
BLLN
BLLN
CRC
CRC
Q1 26
Q4 25
Q3 25
0.29×
Q2 25
0.30×
Q1 25
0.29×
Q4 24
0.32×
Q3 24
0.32×
Q2 24
0.57×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BLLN
BLLN
CRC
CRC
Operating Cash FlowLast quarter
$13.8M
$99.0M
Free Cash FlowOCF − Capex
$6.5M
$-32.0M
FCF MarginFCF / Revenue
7.7%
-26.9%
Capex IntensityCapex / Revenue
8.8%
Cash ConversionOCF / Net Profit
2.42×
TTM Free Cash FlowTrailing 4 quarters
$380.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BLLN
BLLN
CRC
CRC
Q1 26
$99.0M
Q4 25
$235.0M
Q3 25
$13.8M
$279.0M
Q2 25
$165.0M
Q1 25
$186.0M
Q4 24
$206.0M
Q3 24
$220.0M
Q2 24
$97.0M
Free Cash Flow
BLLN
BLLN
CRC
CRC
Q1 26
$-32.0M
Q4 25
$115.0M
Q3 25
$6.5M
$188.0M
Q2 25
$109.0M
Q1 25
$131.0M
Q4 24
$118.0M
Q3 24
$141.0M
Q2 24
$63.0M
FCF Margin
BLLN
BLLN
CRC
CRC
Q1 26
-26.9%
Q4 25
16.9%
Q3 25
7.7%
26.3%
Q2 25
15.5%
Q1 25
16.1%
Q4 24
14.3%
Q3 24
16.2%
Q2 24
15.3%
Capex Intensity
BLLN
BLLN
CRC
CRC
Q1 26
Q4 25
17.7%
Q3 25
8.8%
12.7%
Q2 25
8.0%
Q1 25
6.8%
Q4 24
10.7%
Q3 24
9.1%
Q2 24
8.3%
Cash Conversion
BLLN
BLLN
CRC
CRC
Q1 26
Q4 25
19.58×
Q3 25
2.42×
4.36×
Q2 25
0.96×
Q1 25
1.62×
Q4 24
6.24×
Q3 24
0.64×
Q2 24
12.13×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

BLLN
BLLN

Prenatal$74.1M89%
Oncology$8.7M10%

CRC
CRC

Segment breakdown not available.

Related Comparisons